Intensity Therapeutics, Inc. (INTS)
4.23
-0.02
(-0.47%)
USD |
NASDAQ |
Aug 31, 11:27
Intensity Therapeutics Debt to Equity Ratio : 0.0103 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0103 |
| March 31, 2026 | 0.0102 |
| December 31, 2025 | 0.0093 |
| September 30, 2025 | 0.0163 |
| June 30, 2025 | 0.0572 |
| March 31, 2025 | 0.3922 |
| December 31, 2024 | 0.0473 |
| September 30, 2024 | 0.0522 |
| June 30, 2024 | 0.0283 |
| March 31, 2024 | 0.0161 |
| December 31, 2023 | 0.012 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.0098 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | -0.7577 |
| December 31, 2022 | -0.8812 |
| September 30, 2022 | -0.5343 |
| June 30, 2022 | -0.9204 |
| March 31, 2022 | -2.980 |
| December 31, 2021 | 1.780 |
| March 31, 2021 | 0.064 |
| December 31, 2020 | 0.0586 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.0127 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 11.52M |
| Total Liabilities (Quarterly) | 2.307M |
| Shareholders Equity (Quarterly) | 9.214M |
| Current Ratio | 5.002 |
| Net Debt Paydown Yield | 0.06% |